This was also confirmed by other, later analyses comparing the use of all SGLT-2 inhibitors, including dapagliflozin, in women with type 2 diabetes, with the use of dipeptidyl peptidase-4 inhibitors (DPP-4is) [71]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.